CHMP2B

Across TCGA pan-cancer cohorts, CHMP2B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CHMP2B’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where CHMP2B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CHMP2B is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

LUAD, HNSC, and PDAC are the cancer types where CHMP2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHMP2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+0.393	<.001	9	view →
HNSC	Male	IV	−0.340	<.001	8	view →
PDAC	Male	All	+0.453	.006	4	view →
CCRCC	All	All	−0.111	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CHMP2B–LUAD

Open the LUAD breakdown →